3 completed, 2 active not recruiting, 2 recruiting, 1 unknown. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 3, Active not recruiting 2, Recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Acute Biphenotypic Leukemia: new trials by email Literature Review of Acute Biphenotypic Leukemia trials Research Report on Acute Biphenotypic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Cyclophosphamide, Fludarabine, Total Body Irradiation - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 | Withdrawn | Ossium Health, Inc. | 2022-09-01 | 2026-02-24 | |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-04-17 |
| HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection - Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 24 | 2018-02-23 | 2026-05-18 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | University of Washington | 84 | 2016-12-01 | 2023-07-05 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2015-12-16 | 2022-06-30 |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis - Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2015-12-15 | 2026-08-26 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 199 | 2014-01-23 | 2020-01-10 |
| NK Cells in Cord Blood Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 1 | Unknown | M.D. Anderson Cancer Center | 13 | 2013-05-03 | 2020-02-11 |
Leukemia, Biphenotypic, Acute (9) · Leukemia, Myeloid, Acute (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Myelodysplastic Syndromes (4) · Leukemia (3) · Neoplasm, Residual (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma, Non-Hodgkin (2) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Hematologic Diseases (1) · Leukemia, B-Cell (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Leukemia, Lymphoid (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Hematologic Diseases (8) · Leukemia, Myeloid (8) · Leukemia (6) · Bone Marrow Diseases (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (4)
Cyclophosphamide (5) · fludarabine phosphate (5) · Filgrastim (4) · Cladribine (3) · Cytarabine (3) · Granulocyte Colony-Stimulating Factor (3) · Mitoxantrone (3) · Mycophenolic Acid (3) · Bone Marrow Transplantation (2) · Melphalan (2) · Mesna (2) · Whole-Body Irradiation (2) · Busulfan (1) · CT-P10 (1) · CTL019 chimeric antigen receptor (1)
Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (2) · Ossium Health, Inc. (2) · University of Washington (2) · City of Hope Medical Center (1)
United States (8)
Anna Halpern (1) · Chitra Hosing (1) · Elizabeth Krakow (1) · Lihua E. Budde (1) · Mary-Beth M. Percival (1) · Partow Kebriaei (1) · Roland Walter (1)
PMID 36402456, PMID 37339483, PMID 38683966, PMID 40535475, PMID 42681647
P30CA015704 (2), P30CA016672 (1)